SARS-CoV-2 infection produces a quantifiable immune response. Post-infection immunity
consists of a humoral and cell-mediated response, which appears to reduce the risk of
SARS-CoV-2 re-infection for at least 6 months in the healthy population. It is reasonable
to assume that SARS-COV-2 vaccination may also induce a similar response.

In immunomediated renal disease patients, it is not known what the antibody response is,
what factors can potentially influence it, other than immunosuppressive therapy. This
information, on the other hand, is useful not only in identifying individuals at risk of
infection despite vaccination but it can help to personalize the vaccination schedule.

All patients with immune-mediated renal diseases undergoing the complete vaccination
cycle (one or two doses depending on the type of vaccine used) against SARS-CoV-2, and
for whom at least one dosage of anti-SARS-CoV-2 antibodies are eligible.

After obtaining signed informed consent, personal data, underlying disease, biochemical
parameters (including immunoglobulin assay and lymphocyte typing, if available), present
or previous comorbidities, immunosuppressive therapies, dosage of SARS-CoV-2 IgG
antiSpike and/or antiRBD/Spike antibodies, the date of vaccinations and the type of
vaccine performed will be extracted.

The data are all present in the patients' inpatient and/or outpatient medical records, as
part of normal clinical management and completely independent of participation in the
current clinical trial.

The interview with the patient will show the possible appearance of COVID-19 infection,
the date of his diagnosis, confirmed by a positive molecular swab, the degree of severity
and the clinical course.